drugset / Trial / NCT04577755

Pomalidomide Treatment in Patients With Kaposi Sarcoma

NCT04577755 ↗

Phase 2 Active not recruiting 45 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.

Timeline

Start
2022-03-18
Primary completion
2027-02-04
Completion
2027-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Pomalidomide Other / unclassified — Oral

Indications